[HTML][HTML] Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial
A Nasser, T Liranso, T Adewole, N Fry, JT Hull… - Clinical Therapeutics, 2021 - Elsevier
Abstract Purpose SPN-812 (viloxazine extended-release) is under investigation for the
treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. This …
treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. This …
A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention …
A Nasser, T Liranso, T Adewole, N Fry, JT Hull… - Clinical …, 2020 - Elsevier
Purpose The limitations of current US Food and Drug Administration (FDA)–approved
medications for the treatment of attention-deficit/hyperactivity disorder (ADHD) set the need …
medications for the treatment of attention-deficit/hyperactivity disorder (ADHD) set the need …
[HTML][HTML] A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD
A Nasser, T Liranso, T Adewole, N Fry… - Psychopharmacology …, 2021 - ncbi.nlm.nih.gov
Objectives: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in
pediatric subjects with ADHD. Here, we report the results of a fourth trial. Methods: Eligible …
pediatric subjects with ADHD. Here, we report the results of a fourth trial. Methods: Eligible …
A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD
JK Johnson, T Liranso, K Saylor… - Journal of attention …, 2020 - journals.sagepub.com
Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-
release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study …
release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study …
[HTML][HTML] Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis …
SV Faraone, R Gomeni, JT Hull, GD Busse, Z Melyan… - Psychiatry …, 2021 - Elsevier
Abstract Machine learning (ML) was used to determine whether early response can predict
efficacy outcome in pediatric subjects with ADHD treated with SPN-812. We used data from …
efficacy outcome in pediatric subjects with ADHD treated with SPN-812. We used data from …
[HTML][HTML] Evidence-based pharmacological treatment options for ADHD in children and adolescents
K Mechler, T Banaschewski, S Hohmann… - Pharmacology & …, 2022 - Elsevier
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder
characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. Its …
characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. Its …
A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit …
A Nasser, JT Hull, SA Chaturvedi, T Liranso, O Odebo… - CNS drugs, 2022 - Springer
Background and objective Attention-deficit/hyperactivity disorder is a neurodevelopmental
disorder that typically begins in childhood and often persists into adulthood. Recent phase III …
disorder that typically begins in childhood and often persists into adulthood. Recent phase III …
Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD
SH Kollins, R Jain, M Brams, S Segal, RL Findling… - …, 2011 - publications.aap.org
OBJECTIVE: To assess the efficacy and safety of clonidine hydrochloride extended-release
tablets (CLON-XR) combined with stimulants (ie, methylphenidate or amphetamine) for …
tablets (CLON-XR) combined with stimulants (ie, methylphenidate or amphetamine) for …
The effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit/hyperactivity disorder (ADHD) in children and …
A Nasser, JT Hull, T Liranso, GD Busse… - Neuropsychiatric …, 2021 - Taylor & Francis
Purpose The ADHD Rating Scale (ADHD-RS) assesses 18 symptoms of inattention and
hyperactivity/impulsivity and has been used in many clinical trials to evaluate the treatment …
hyperactivity/impulsivity and has been used in many clinical trials to evaluate the treatment …
Viloxazine in the treatment of attention deficit hyperactivity disorder
AN Edinoff, HA Akuly, JH Wagner… - Frontiers in …, 2021 - frontiersin.org
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental
disorder in children. Over the past twenty years, research on the disease and its …
disorder in children. Over the past twenty years, research on the disease and its …